PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ...

PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty ...

Zusduri is expected to be available on or around July 1, 2025. The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade ...

In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today ...

Frequent adverse events are associated with bacillus Calmette–Guérin (BCG) therapy; there is a need, therefore, for new therapies to treat superficial bladder cancer effectively and safely. Apaziquone ...

The current standard of care for high-risk superficial bladder cancer is intravesical bacillus Calmette–Guérin (BCG). Electromotive mitomycin has also shown efficacy against high-risk superficial ...

INTRAVESICAL INSTILLATION of cytotoxic chemotherapy or immunotherapy is used to treat existing tumors, reduce or postpone tumor recurrence, and delay or prevent tumor progression and subsequent ...

Bladder cancer patterns of pelvic failure: Implications for adjuvant radiation therapy. Background: Combination chemotherapy is the standard of care for neoadjuvant, adjuvant, and metastatic bladder ...

A 2-dose regimen effectively delivers mitomycin C to the bladder tissue before TURBT, investigators reported. Administering 2 doses of neoadjuvant intravesical mitomycin-C before transurethral ...

Please provide your email address to receive an email when new articles are posted on . A single treatment with preoperative intravesical electromotive instillation of mitomycin-C decreased the risk ...

Gemcitabine delivered via intravesical instillation reduced the risk of recurrence in patients with low-grade non-muscle-invasive urothelial cancer, according to results of a randomized phase III ...